secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-09-05T23:59:59+00:00
Accession:  0001367644-25-000183
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions awarded $30M BARDA contract modification for CYFENDUS anthrax vaccine
--------------------------------------------------------------------------------

- Modification No. 20 valued at $30M for additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).
- Deliveries begin calendar 2025 and are scheduled to be completed by March 2026.
- Follows a prior $50M modification in December 2024 for the same vaccine.
- CYFENDUS received FDA approval in July 2023 as a two-dose post-exposure prophylaxis for adults 18-65.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/0001367644-25-000183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/ebs-20250902.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer